20 Stocks Insiders Bought in April After Trump’s Tariff Rollout

2. STAAR Surgical Company (NASDAQ:STAA)

STAAR Surgical designs, develops, and manufactures implantable lenses and delivery systems for treating visual disorders like myopia, hyperopia, astigmatism, and presbyopia. The Lake Forest, California-based company sells its products to healthcare providers globally, including ophthalmic surgeons, hospitals, and vision centers, with direct sales in several countries.

This month, one insider purchased $13.63 million worth of STAAR Surgical shares at an average price of $16.18 per share. Year-to-date, the stock is down 33.55%, trading at $16.14 per share. Over the past 12 months, STAAR Surgical shares dropped 67.39%.

For fiscal year 2024, the company reported net sales of $313.9 million, compared to $322.4 million in the prior year. The decrease in net sales was driven largely by the significant decline in China revenue in the fourth quarter of 2024. Net loss was $20.2 million, which compares to net income of $21.3 million in 2023. Adjusted EBITDA amounted to $23.2 million, or $0.47 per share, compared to $56.8 million, or $1.15 per share a year ago.

According to 10 analysts’ estimates, STAAR Surgical stock is a “Hold” with a price target of $25.29. The average price target suggests a 56.66% potential upside from the latest price.